Systemic hypoferraemia and severity of hypoxaemic respiratory failure in COVID-19

COVID-19 caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) was declared a pandemic on March 11, 2020, with the major causes of mortality being progressive hypoxia or multiorgan dysfunction¹. Previous work has identified risk factors associated with respiratory failure in patients with COVID-19 which include older age, neutrophilia, elevated inflammatory and coagulation markers, and hyperferritinaemia². Inflammation in general is often accompanied by systemic hypoferraemia³, and systemic hypoferraemia disturbs normal human responses to hypoxia-induced induced lung injury⁴, which is of considerable concern in patients with COVID-19. However, although ferritin concentrations in COVID-19 are well reported, there are no published data on other markers of iron status. Therefore, we sought to characterise iron parameters, including serum iron, in COVID-19 intensive care unit (ICU) patients and relate these to disease severity.

We retrospectively evaluated any serum iron profiles that were measured in critically ill patients with COVID-19 within 24 hours of admission to the ICU, John Radcliffe Hospital, Oxford, UK between March 31, 2020 and April 25, 2020. Relevant clinical and laboratory data were extracted from routinely collected healthcare records. We stratified patients according to severity of hypoxaemic respiratory failure on admission to ICU - severe (PaO₂/FiO₂ ratio < 100 mmHg) versus non-severe (PaO₂/FiO₂ ratio 100-300 mmHg)⁵. Research ethics committee approval was not required for this study as per the UK Health Research Authority Decision tool (http://www.hra-decisiontools.org.uk/research/); the local institutional board (Oxford University Hospitals NHS Foundation Trust Research and Development) approved ethical oversight and waiver of consent. No direct patient identifiable data were collected.

A total of 30 patients were included and their demographic, clinical and laboratory characteristics are shown in Supplementary Table 1. Overall, 17 (57%) patients were male. The median age was 57 years (IQR, 52-64). Compared with patients with non-severe hypoxaemia, patients with severe hypoxaemia had significantly lower levels of serum iron (median 2·3 (IQR, 2·2-2·5) vs 4·3 (IQR, 3·3-5·2) μmol/L, p < 0·001) and lymphocyte counts (mean (SD) 0·50 (0·2) vs. 0·87 (0·4), p = 0·015). There were no statistically significant differences in transferrin saturation and serum ferritin levels between groups (Figure 1A). The area under the curve for receiver operating characteristic curves for serum iron to identify severe hypoxaemia was 0·95; the optimal Youden Index for distinguishing between severe and non-severe hypoxaemia was a serum iron concentration of 2·9 μmol/L (Figure 1B). By linear regression, serum iron was associated with lymphocyte count and PaO₂/FiO₂ (Figures 1C and 1D).

• Download figure
• Open in new tab

Figure 1: Associations between markers of iron status, lymphocyte count and severity of hypoxaemia

Figure legend: 1A Boxplotsshow the 25th, 50th, and 75th percentiles (box); 10th and 90th percentiles (whiskers); and data points (circles) of serum iron, transferrin saturation (Tsat) and serum ferritin, stratified by severity of hypoxemia; IB Receiver Operating Characteristic (ROC) Curve and Youden Index for serum iron in distinguishing severe and non-severe hypoxemia; 1C Correlation serum iron and PaO₂/FiO₂ ratio; ID Correlation between serum iron and lymphocyte count. Mann-Whitney rank sum test was used to compare nonparametric continuous variables between these two groups. All statistical tests were 2-tailed, and statistical significance was defined as PQ<Q.05. Analyses were performed using PRISM version 8 (GraphPad Software).

Our findings demonstrate profound hypoferraemia in COVID-19 patients with severe hypoxaemia. Serum iron was lower when compared with other cohorts of non-COVID-19 ICU patients reported previously, including those with sepsis ⁶. Altered iron fluxes have been linked with ICU outcomes previously, and our data indicate that severe hypoferraemia may be detrimental in COVID-19.^{6, 7} The association of serum iron with lymphocyte counts could reflect the requirement of the adaptive immune response for iron⁸ and may be relevant for immune competence in COVID-19.

The cause of hypoferremia is likely to be due to increased hepcidin secondary to inflammation³. Unlike hepcidin, serum iron is measured widely and so could assist with identification and monitoring of severity of disease. Anti-inflammatory drugs such as Tocilizumab may increase serum iron by suppressing hepcidin synthesis, through inhibition of interleukin-6 (which stimulates hepcidin)⁹. In summary, a pathological role of severe hypoferraemia in COVID-19 is plausible, for example via effects on hypoxia sensing and immunity, and potentially treatable, via hepcidin inhibition.